Condition: Advanced Neuroendocrine Carcinomas of The Digestive System · Advanced Neuroendocrine Carcinomas Unknown Primary Origin · Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Neuroendocrine neoplasms (NENs) comprise a heterogeneous family of neoplasms arising from the neuroendocrine cells localized in endocrine glands or from the diffuse neuroendocrine cells such as in the digestive or lung tract. Treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NEC) is primarily based on chemotherapy regimens, primarily platinum, which achieve limited benefit and a median overall survival of approximately 12 months. Currently, new treatments that activate the immune system to stimulate antitumor responses and prolong survival in patients with NECs are being investigated. Given the high levels of DLL3 expression on the cell surface of neuroendocrine tumor cells and its minimal, primarily cytoplasmic, localization in normal tissues, DLL3 is a promising target for the development of T-cell-directed therapies in NECs. Tarlatamab is a HLE BiTE molecule that combines the binding specificities for DLL3 and CD3, which could activate the immune system to fight NEC cells. The main hypothesis is that treatment with tarlatamab, a bispecific anti-DLL3 and anti-CD3 conjugate, either as a single agent or in combination with standard second-line chemotherapy (FOLFIRI) scheme could be an effective treatment option for patients with advanced neuroendocrine carcinomas of the digestive system or unknown primary origin.
This description comes directly from the study's public registry record.
Federico Nepote, M.D., PhD. · +34 93 434 44 12 · investigacion@mfar.net
Jaume Capdevila, M.D., Ph.D. · +34 93 434 44 12 · investigacion@mfar.net
Always discuss trial participation with your own doctor first.
| Brest University Hospital Centre | Brest, Brest, France | Not Yet Recruiting |
| Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux) | Bordeaux, Cedex, France | Not Yet Recruiting |
| Centre Oscar Lambret | Lille, Lille, France | Not Yet Recruiting |
| Hôpital Edouard Herriot (Hospices Civils Lyon) | Lyon, Lyon, France | Not Yet Recruiting |
| Institut de Cancérologie de l'Ouest (Angers/Nantes) | Nantes, Nantes, France | Not Yet Recruiting |
| Centre Hospitalier Universitaire de Toulouse | Toulouse, Toulouse, France | Not Yet Recruiting |
| Institut de Cancérologie de Lorraine (CLCC) Nancy | Vandœuvre-lès-Nancy, Vandœuvre-lès-Nancy Cedex, France | Not Yet Recruiting |
| Gustave Roussy | Villejuif, Villejuif,, France | Not Yet Recruiting |
| Hospital Clínico Universitario de Santiago | Santiago de Compostela, A Coruña, Spain | Not Yet Recruiting |
| H.U Germans Trias i Pujols | Badalona, Barcelona, Spain | Not Yet Recruiting |
| H.U. Vall d'Hebron | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Universitario de Burgos (HUBU) | Burgos, Burgos, Spain | Not Yet Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07061080